A previous study from our laboratory published by Lowery et al. [23] showed tumor regrowth upon prexasertib withdrawal in the pediatric aRMS CDX model SJC-Rh30, suggesting the development of acquired resistance to CHK1 inhibition or regrowth of residual tumor. The gene discussed is CHEK1; the disease is neoplasm.